The pandemic allowed us to examine how CVID patients reacted to a novel antigen.
Here we characterized B cell function. across multiple immunization events.
www.medrxiv.org/content/10.1...
The pandemic allowed us to examine how CVID patients reacted to a novel antigen.
Here we characterized B cell function. across multiple immunization events.
www.medrxiv.org/content/10.1...
Lasse and Emil from our group did a fantastic deep dive into all clinical trials being conducted using CAR NKs. Check out our review: link.springer.com/article/10.1... #CAR #NK #Immunology
Lasse and Emil from our group did a fantastic deep dive into all clinical trials being conducted using CAR NKs. Check out our review: link.springer.com/article/10.1... #CAR #NK #Immunology
Here we provide a method for encapsulating >500.000 single CAR T cells with single target cells in droplets together with reagents to examine killing using standard flow cytometry:
app.jove.com/t/67657/drop...
Here we provide a method for encapsulating >500.000 single CAR T cells with single target cells in droplets together with reagents to examine killing using standard flow cytometry:
app.jove.com/t/67657/drop...
@natcomms.bsky.social, we described that immune cells can adapt to IFNg-driven escape, enhancing their fitness and thereby counteracting tumour escape www.nature.com/articles/s41...
@natcomms.bsky.social, we described that immune cells can adapt to IFNg-driven escape, enhancing their fitness and thereby counteracting tumour escape www.nature.com/articles/s41...
"In nature, the occurrence of this single mutation could be an indicator of human pandemic risk"
#IDSky #InfectiousDiseases #EpiSky #Epidemics
www.science.org/doi/10.1126/...
"In nature, the occurrence of this single mutation could be an indicator of human pandemic risk"
#IDSky #InfectiousDiseases #EpiSky #Epidemics
www.science.org/doi/10.1126/...
direct.mit.edu/qss/article/...
A 🧵 1/n
#AcademicSky #PhDchat #ScientificPublishing #SciPub
direct.mit.edu/qss/article/...
A 🧵 1/n
#AcademicSky #PhDchat #ScientificPublishing #SciPub
- 69 pts, 27% 3+ LOT, no bridging in 14d between apheresis & infusion
- 91% got fresh product
- ORR 73%, CR 49%
- 1-yr PFS/OS 42%/72%, mDOR 11 mos
- all CRS G1-2, 3 pts G3 ICANS
Reducing V2V & B2V time always good! #lymsm #celltherapy
- 69 pts, 27% 3+ LOT, no bridging in 14d between apheresis & infusion
- 91% got fresh product
- ORR 73%, CR 49%
- 1-yr PFS/OS 42%/72%, mDOR 11 mos
- all CRS G1-2, 3 pts G3 ICANS
Reducing V2V & B2V time always good! #lymsm #celltherapy